# Intranasal Insulin in Parkinson's Disease

> **NCT04251585** · PHASE2 · COMPLETED · sponsor: **HealthPartners Institute** · enrollment: 31 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Regular Novolin R
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04251585
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-04
- **Primary completion:** 2024-08-27
- **Final completion:** 2024-08-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04251585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04251585, "Intranasal Insulin in Parkinson's Disease". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04251585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*